Prediction of Sustained Virological Response to Peginterferon-based Therapy for Chronic Hepatitis C: Regression Analysis of a Cohort from Rio Grande do Sul, Brazil

AIM: Peginterferon plus ribavirin (peg-IFN/RBV) is still the standard of care for treatment of hepatitis C virus (HCV) in many countries. Given the high toxicity of this regimen, our study aimed to develop a prediction tool that can identify which patients are unlikely to benefit from peg-IFN/RBV an...

Descripción completa

Detalles Bibliográficos
Autores principales: V Picon, Rafael, Fendt, Lúcia, Amaral, Karine, D Picon, Paulo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663770/
https://www.ncbi.nlm.nih.gov/pubmed/29201768
http://dx.doi.org/10.5005/jp-journals-10018-1207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663770/
https://www.ncbi.nlm.nih.gov/pubmed/29201768
http://dx.doi.org/10.5005/jp-journals-10018-1207

Ejemplares similares